The potential effects of excessive ROS increase following auranofin or auranofin/L-BSO treatment on increased EGFRvIII phosphorylation, Cbl-mediated ubiquitination of EGFRvIII, its decreased stability and oncogenic properties, deserve to be explored in EGFRvIII-positive GBM. The gene discussed is CBL; the disease is glioblastoma.